Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments—a WWARN individual patient data meta-analysis

[1]  J. Rayner,et al.  Uncovering the essential genes of the human malaria parasite Plasmodium falciparum by saturation mutagenesis , 2018, Science.

[2]  P. Rosenthal,et al.  Plasmodium falciparum Falcipain-2a Polymorphisms in Southeast Asia and Their Association With Artemisinin Resistance , 2018, The Journal of infectious diseases.

[3]  T. Horii,et al.  Artemisinin-Resistant Plasmodium falciparum with High Survival Rates, Uganda, 2014–2016 , 2018, Emerging infectious diseases.

[4]  Zbynek Bozdech,et al.  Oxidative stress and protein damage responses mediate artemisinin resistance in malaria parasites , 2018, PLoS pathogens.

[5]  P. Ringwald,et al.  Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015 , 2018, Malaria Journal.

[6]  M. Fukuda,et al.  Emergence and Spread of kelch13 Mutations Associated with Artemisinin Resistance in Plasmodium falciparum Parasites in 12 Thai Provinces from 2007 to 2016 , 2018, Antimicrobial Agents and Chemotherapy.

[7]  Daniel B. Roche,et al.  Functional analysis of Plasmodium falciparum subpopulations associated with artemisinin resistance in Cambodia , 2017, Malaria Journal.

[8]  F. Nosten,et al.  Plasmodium falciparum Kelch 13 mutations and treatment response in patients in Hpa-Pun District, Northern Kayin State, Myanmar , 2017, Malaria Journal.

[9]  Jim Stalker,et al.  Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study , 2017, bioRxiv.

[10]  Nicholas J White,et al.  Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam. , 2017, The Lancet. Infectious diseases.

[11]  K. Thimasarn,et al.  Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009–2013) , 2017, Malaria Journal.

[12]  P. de Mol,et al.  Molecular surveillance of Plasmodium falciparum resistance to artemisinin-based combination therapies in the Democratic Republic of Congo , 2017, PloS one.

[13]  S. Schaffner,et al.  Artemisinin resistance without pfkelch13 mutations in Plasmodium falciparum isolates from Cambodia , 2017, Malaria Journal.

[14]  Mehul Dhorda,et al.  The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study , 2017, The Lancet. Infectious diseases.

[15]  D. Fidock,et al.  Plasmodium falciparum K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness In Vitro , 2017, mBio.

[16]  P. Ringwald,et al.  Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies , 2017, Malaria Journal.

[17]  J. Simpson,et al.  Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort , 2017, Proceedings of the National Academy of Sciences.

[18]  D. Kwiatkowski,et al.  Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. , 2017, The Lancet. Infectious diseases.

[19]  O. Doumbo,et al.  PF3D7_1343700 KELCH PROPELLER (K13-PROPELLER) POLYMORPHISMS AND ARTESUNATE MONOTHERAPY EFFICACY IN UNCOMPLICATED MALARIA TREATMENT IN MALI , 2017, BMJ Global Health.

[20]  C. Dolecek,et al.  K13 Propeller Mutations in Plasmodium falciparum Populations in Regions of Malaria Endemicity in Vietnam from 2009 to 2016 , 2017, Antimicrobial Agents and Chemotherapy.

[21]  Dhruviben S. Patel,et al.  Molecular Epidemiology of Plasmodium falciparum kelch13 Mutations in Senegal Determined by Using Targeted Amplicon Deep Sequencing , 2017, Antimicrobial Agents and Chemotherapy.

[22]  François Nosten,et al.  Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance , 2016, bioRxiv.

[23]  F. Mockenhaupt,et al.  Artemisinin Resistance-Associated K13 Polymorphisms of Plasmodium falciparum in Southern Rwanda, 2010-2015. , 2016, The American journal of tropical medicine and hygiene.

[24]  P. Salgueiro,et al.  Plasmodium falciparum Genetic Diversity in Continental Equatorial Guinea before and after Introduction of Artemisinin-Based Combination Therapy , 2016, Antimicrobial Agents and Chemotherapy.

[25]  F. Nosten,et al.  Population Parameters Underlying an Ongoing Soft Sweep in Southeast Asian Malaria Parasites , 2016, Molecular biology and evolution.

[26]  Leann Tilley,et al.  Artemisinin Action and Resistance in Plasmodium falciparum. , 2016, Trends in parasitology.

[27]  C. Obua,et al.  Prevalence of K13-propeller gene polymorphisms among Plasmodium falciparum parasites isolated from adult symptomatic patients in northern Uganda , 2016, BMC Infectious Diseases.

[28]  C. Rogier,et al.  A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. , 2016, The New England journal of medicine.

[29]  Zbynek Bozdech,et al.  Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai–Myanmar Border (2003–2013): The Role of Parasite Genetic Factors , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  F. Seeber.  Faculty Opinions recommendation of Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. , 2016 .

[31]  J. Barnwell,et al.  Independent Emergence of the Plasmodium falciparum Kelch Propeller Domain Mutant Allele C580Y in Guyana. , 2016, The Journal of infectious diseases.

[32]  C. Severini,et al.  Molecular surveillance of antimalarial drug resistance related genes in Plasmodium falciparum isolates from Eritrea. , 2016, Acta tropica.

[33]  E. Ashley,et al.  Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study , 2016, Malaria Journal.

[34]  Nicholas P. J. Day,et al.  Genomic epidemiology of artemisinin resistant malaria. , 2016, eLife.

[35]  Dongmei Zhang,et al.  Distinctive origin of artemisinin-resistant Plasmodium falciparum on the China-Myanmar border , 2016, Scientific Reports.

[36]  T. Bousema,et al.  Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children , 2016, Malaria Journal.

[37]  Fangli Lu,et al.  Polymorphisms of the artemisinin resistant marker (K13) in Plasmodium falciparum parasite populations of Grande Comore Island 10 years after artemisinin combination therapy , 2015, Parasites & Vectors.

[38]  B. Pradines,et al.  K13-Propeller Polymorphisms in Plasmodium falciparum Isolates from Patients in Mayotte in 2013 and 2014 , 2015, Antimicrobial Agents and Chemotherapy.

[39]  L. Cui,et al.  Artemisinin Resistance at the China-Myanmar Border and Association with Mutations in the K13 Propeller Gene , 2015, Antimicrobial Agents and Chemotherapy.

[40]  O. Doumbo,et al.  Polymorphisms in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara, Mali. , 2015, The American journal of tropical medicine and hygiene.

[41]  P. Rosenthal,et al.  Lack of Artemisinin Resistance in Plasmodium falciparum in Uganda Based on Parasitological and Molecular Assays , 2015, Antimicrobial Agents and Chemotherapy.

[42]  Richard D Riley,et al.  Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement , 2015 .

[43]  Shui-sen Zhou,et al.  A Single Mutation in K13 Predominates in Southern China and Is Associated With Delayed Clearance of Plasmodium falciparum Following Artemisinin Treatment. , 2015, The Journal of infectious diseases.

[44]  S. Han,et al.  Molecular assessment of artemisinin resistance markers, polymorphisms in the k13 propeller, and a multidrug-resistance gene in the eastern and western border areas of Myanmar. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  Scott Emrich,et al.  A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria , 2015, Nature.

[46]  J. Barnwell,et al.  Selection and Spread of Artemisinin-Resistant Alleles in Thailand Prior to the Global Artemisinin Resistance Containment Campaign , 2015, PLoS pathogens.

[47]  R. Maude,et al.  Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker , 2015, The Lancet. Infectious diseases.

[48]  Steve M. Taylor,et al.  Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. , 2015, The Journal of infectious diseases.

[49]  John C. Tan,et al.  Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. , 2015, The Journal of infectious diseases.

[50]  D. Kwiatkowski,et al.  Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance , 2015, Science.

[51]  D. Fidock,et al.  K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates , 2015, Science.

[52]  Gilean McVean,et al.  Genetic architecture of artemisinin-resistant Plasmodium falciparum , 2015, Nature Genetics.

[53]  F. Nosten,et al.  Pooled Sequencing and Rare Variant Association Tests for Identifying the Determinants of Emerging Drug Resistance in Malaria Parasites , 2014, Molecular biology and evolution.

[54]  D. Kwiatkowski,et al.  K13-Propeller Polymorphisms in Plasmodium falciparum Parasites From Sub-Saharan Africa , 2014, The Journal of infectious diseases.

[55]  A. Rosanas-Urgell,et al.  Delayed Parasite Clearance after Treatment with Dihydroartemisinin-Piperaquine in Plasmodium falciparum Malaria Patients in Central Vietnam , 2014, Antimicrobial Agents and Chemotherapy.

[56]  P. Rosenthal,et al.  Polymorphisms in K13 and Falcipain-2 Associated with Artemisinin Resistance Are Not Prevalent in Plasmodium falciparum Isolated from Ugandan Children , 2014, PloS one.

[57]  D. Kwiatkowski,et al.  Spread of artemisinin resistance in Plasmodium falciparum malaria. , 2014, The New England journal of medicine.

[58]  P. Wilairat,et al.  Origin of robustness in generating drug-resistant malaria parasites. , 2014, Molecular biology and evolution.

[59]  N. Day,et al.  Laboratory Detection of Artemisinin-Resistant Plasmodium falciparum , 2014, Antimicrobial Agents and Chemotherapy.

[60]  B. Genton,et al.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.

[61]  C. Plowe.  Malaria: Resistance nailed , 2013, Nature.

[62]  Saorin Kim,et al.  Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. , 2013, The Lancet. Infectious diseases.

[63]  P. Newton,et al.  Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives , 2013, Malaria Journal.

[64]  F. Nosten,et al.  Genetic Evaluation of the Performance of Malaria Parasite Clearance Rate Metrics , 2013, The Journal of infectious diseases.

[65]  Juliana M. Sá,et al.  Plasmodium falciparum Clearance Rates in Response to Artesunate in Malian Children With Malaria: Effect of Acquired Immunity , 2013, The Journal of infectious diseases.

[66]  R. Haque,et al.  Current Status of Artemisinin-Resistant falciparum Malaria in South Asia: A Randomized Controlled Artesunate Monotherapy Trial in Bangladesh , 2012, PloS one.

[67]  Joana C. Silva,et al.  Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia , 2012, Proceedings of the National Academy of Sciences.

[68]  K. Silamut,et al.  Effect of High-Dose or Split-Dose Artesunate on Parasite Clearance in Artemisinin-Resistant Falciparum Malaria , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[69]  C. Dolecek,et al.  In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam , 2012, Malaria Journal.

[70]  O. Doumbo,et al.  No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. , 2012, The American journal of tropical medicine and hygiene.

[71]  F. Nosten,et al.  Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study , 2012, The Lancet.

[72]  P. Newton,et al.  A Major Genome Region Underlying Artemisinin Resistance in Malaria , 2012, Science.

[73]  Mayfong Mayxay,et al.  No Evidence for Spread of Plasmodium falciparum Artemisinin Resistance to Savannakhet Province, Southern Laos , 2012, The American journal of tropical medicine and hygiene.

[74]  K. Stepniewska,et al.  Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator , 2011, Malaria Journal.

[75]  N. White.  The parasite clearance curve , 2011, Malaria Journal.

[76]  S. Tyner,et al.  Artesunate Dose Escalation for the Treatment of Uncomplicated Malaria in a Region of Reported Artemisinin Resistance: A Randomized Clinical Trial , 2011, PloS one.

[77]  R. Price,et al.  In vivo parasitological measures of artemisinin susceptibility. , 2010, The Journal of infectious diseases.

[78]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[79]  M. Fukuda,et al.  Evidence of artemisinin-resistant malaria in western Cambodia. , 2008, The New England journal of medicine.

[80]  X. Su,et al.  Genome-Wide Compensatory Changes Accompany Drug- Selected Mutations in the Plasmodium falciparum crt Gene , 2008, PloS one.

[81]  M. Ashton,et al.  Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. , 2003, British journal of clinical pharmacology.

[82]  Artemisinin resistance and artemisinin-based combination therapy efficacy , 2018 .

[83]  Key Messages.  Artemisinin and artemisinin-based combination therapy resistance , 2016 .

[84]  L. Basco.  Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies. , 2011 .